Ibrance in HER-2+, PATINA trial – pro
The Phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE®) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In the study, which is sponsored by AFT, median PFS was 44.3 months (95% CI: 32.4-60.9) for patients treated with palbociclib in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy and 29.1 months (95% CI: 23.3-38.6) for patients treated with anti-HER2 therapy and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94; unstratified 1-sided p= 0.0074]. This represents an extension in median PFS of more than 15 months. Overall survival, a secondary endpoint, was not yet mature at the time of the analysis.
https://www.news-medical.net/news/20241212/PATINA-trial-demonstrates-benefit-of-palbociclib-in-HR2b-HER22b-metastatic-breast-cancer.aspx – Accessed 1/7/2025
Loibl, S. et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Annals of Oncology, Volume 29, viii121
Pegram M, Pietras R, Dang CT, Murthy R, Bachelot T, Janni W, Sharma P, Hamilton E, Saura C. Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer. Ther Adv Med Oncol. 2023 Aug 11;15:17588359231187201.
NCCN Breast Cancer 2025